Top Mupirocin Ointment Brands You Should Consider

Mupirocin ointment, a popular topical antibiotic, is commonly used to treat bacterial skin infections. With numerous brands offering this medication, it's crucial to select one known for its efficacy and safety. Some of the top-rated brands, which consistently receive positive reviews from healthcare professionals and patients, include Centany, Bactroban, and GlaxoSmithKline's offerings. For a comprehensive look at other reputable brands and detailed information on their formulations and pricing, continue reading below.

Illustration of mupirocin ointment

Best brands of mupirocin ointment in 2025

Centany

Centany, a brand of mupirocin ointment, is renowned for its efficacy in treating impetigo caused by Staphylococcus aureus and Streptococcus pyogenes. Each gram of Centany ointment contains 20 mg of mupirocin, and it has been shown to have a high clinical efficacy rate of 94% in treating impetigo, with a pathogen eradication rate of 98%. The ointment is supplied in 15 gram and 30 gram tubes and should be stored at controlled room temperature between 20°C to 25°C (68°F to 77°F). Centany is manufactured by OrthoNeutrogena and distributed by Ortho-McNeil Pharmaceutical, Inc., highlighting its reliability and quality in the market. The product's unique mode of action inhibits bacterial protein synthesis, making it effective against gram-positive bacteria and certain gram-negative bacteria.

Bactroban

Bactroban, a brand of mupirocin ointment, is a leading product in the market, known for its efficacy in treating skin infections such as impetigo and MRSA. The global market for Bactroban Ointment was valued at US$ 324 million in 2023 and is forecasted to reach US$ 379.4 million by 2030, growing at a CAGR of 2.2% during the forecast period 2024-2030. Bactroban ointment, containing 20 mg of mupirocin per gram, is widely used in clinical settings due to its potent antibacterial properties. The brand is particularly dominant in North America, which accounted for the largest share of the global market in 2022. Bactroban is manufactured by GlaxoSmithKline, a prominent player in the pharmaceutical industry. For more detailed information, you can visit the Bactroban Ointment page.

Glenmark

Glenmark Pharmaceuticals is a leading manufacturer in the mupirocin ointment market, holding a significant 37% revenue market share. The company's dominance is evident in its substantial contribution to the global market, which was valued at US$ 463 million in 2023 and is expected to reach US$ 579 million by 2030, growing at a CAGR of 3.2% during the forecast period 2024-2030. Glenmark's product quality and market presence are crucial factors in its success, although recent market withdrawals due to stability issues have been noted. Despite these challenges, Glenmark remains a key player, with North America being the largest consumption region, holding 35% of the revenue market share. The company's products are widely recognized and used in various medical settings. For more detailed information on Glenmark's mupirocin ointment, you can visit this link.

Sandoz

Sandoz, a subsidiary of Novartis AG, is a prominent player in the global Mupirocin Ointment market, known for its high-quality and effective topical antibiotic treatments. The company's Mupirocin Ointment is widely used for the treatment of impetigo and other skin and soft tissue infections, driven by its efficacy against Staphylococcus aureus and Streptococcus pyogenes. With a market valued at approximately USD 440 million in 2022, Sandoz contributes significantly to the market's projected growth at a CAGR of around 4% from 2023 to 2028. The company's strong presence in various clinical settings, including hospitals and clinics, further solidifies its position in the market. Sandoz's commitment to innovation and patient care has made it a trusted brand among healthcare providers.

Taro Pharmaceuticals

Taro Pharmaceuticals is a notable producer of mupirocin ointment, known for its high-quality and bioequivalent products. In 2005, Taro received FDA approval for its Mupirocin Ointment USP, 2%, an equivalent to GlaxoSmithKline's Bactroban Ointment. This approval marked a significant milestone in expanding access to effective topical antibiotic treatments. Taro's mupirocin ointment contributes to the global market, which was valued at approximately USD 440 million in 2022 and is projected to grow at a CAGR of around 4% from 2023 to 2028. Taro's commitment to research and development ensures continuous innovation in pharmaceutical products. For more details, visit the official news release.

Teva Pharmaceuticals

Teva Pharmaceuticals is a leading producer of mupirocin ointment, known for its extensive global presence and commitment to providing high-quality, affordable medicines. With over 37,000 employees and operations in 58 markets, Teva is a significant player in the pharmaceutical industry, producing approximately 76 billion tablets and capsules annually. The company's robust product portfolio and strong R&D capabilities enable it to develop and market a wide range of medicines, including mupirocin ointment, which is crucial for treating skin and soft tissue infections. Teva's mupirocin ointment is part of its comprehensive generics business, which holds a top three leadership position in many countries. The company's focus on innovation and patient access has made it a trusted name in the healthcare sector.

Perrigo

Perrigo is a significant player in the global Mupirocin Ointment market, known for its high-quality topical antibiotic products. The company contributes to the market growth driven by the increasing prevalence of skin and soft tissue infections, particularly impetigo. As of 2023, the global Mupirocin Ointment market, in which Perrigo participates, was valued at approximately USD 463 million and is expected to reach USD 579 million by 2030, growing at a CAGR of 3.2% during the forecast period from 2024 to 2030. North America, where Perrigo has a strong presence, holds 35% of the revenue market share. The company's involvement in strategic initiatives and its robust distribution network further solidify its position in the market. For more detailed insights, you can view the market reports.

Fougera Pharmaceuticals

Fougera Pharmaceuticals is a leading manufacturer of high-quality topical products, including mupirocin ointment, with a legacy spanning over 162 years. As a pioneer in the generics industry since the 1960s, Fougera is renowned for its innovative products and commitment to safety and efficacy. The company's "Make No Compromises" philosophy has driven its success, with Fougera receiving numerous FDA approvals for its topical treatments. In the U.S., generics like those produced by Fougera fill 78% of all prescriptions, highlighting the company's significant contribution to affordable healthcare. Fougera's products, including mupirocin ointment, are widely trusted by healthcare providers and patients alike.

Glenmark Pharmaceuticals

Glenmark Pharmaceuticals is a leading manufacturer of mupirocin ointment, holding a significant 37% revenue market share in the global market. The company's dominance is evident in its strong presence in regions like North America, which accounts for 35% of the market share, and China, with a 22% share. The global mupirocin ointment market, valued at US$ 463 million in 2023, is expected to reach US$ 579 million by 2030, growing at a CAGR of 3.2% during the forecast period. Glenmark's robust position in the dermatology segment, with a 21% growth in value as per MAT September data, further solidifies its reputation as a top producer. The company's extensive product portfolio and strong market presence make it a key player in the mupirocin ointment market.

Sun Pharmaceutical Industries

Sun Pharmaceutical Industries Ltd. is a leading producer of mupirocin ointment, leveraging its global presence and extensive manufacturing network of 43 facilities to ensure high-quality and affordable medicines. As the fourth largest specialty generic pharmaceutical company worldwide, Sun Pharma generates $5.4 billion in global revenues and has a significant presence in over 100 countries. The company is among the main players in the mupirocin ointment market, which was valued at $463 million in 2023 and is expected to grow at a CAGR of 3.2% until 2030. Sun Pharma's commitment to competitive pricing and access strategies enhances the availability of mupirocin ointment in both public and private sectors. The company's strong market position is further reinforced by its presence in key emerging markets such as Brazil, Mexico, and South Africa. For more detailed information, visit the Sun Pharma official website.